TDCC shortlisted by United States – India Science and Technology Forum for Development of Low Cost Diagnostic Method for Diabetes Prevention. The method under development in collaboration with Prevendia Inc., California is expected to impact an estimated 68 million non-diabetic non-obese undiagnosed insulin resistant population and 40 million obese insulin resistant population in the US; and an estimated 70-100 million population in India, 50% of whom live in rural areas and 30% in urban areas.